A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: A challenging clinical case in light of the current diagnostic criteria

Autoimmunity Reviews

Volumn 13, Issue 11, 2014, Pages 1142-1148

  Poddighe, Dimitri ^a   Cavagna, Lorenzo ^b   Brazzelli, Valeria ^b   Bruni, Paola ^a   Marseglia, Gian Luigi ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Epstein Barr virus; Hyperferritinemia; Juvenile dermatomyositis; Macrophage activation syndrome

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CEPHALOSPORIN; CETIRIZINE; CYCLOSPORIN; DOBUTAMINE; DOPAMINE; DOXYCYCLINE; FERRITIN; HYDROXYCHLOROQUINE; MACROLIDE; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; AMYOPATHIC JUVENILE DERMATOMYOSITIS; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTIFICIAL VENTILATION; BONE MARROW BIOPSY; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DISEASE COURSE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; FLUID THERAPY; GENERALIZED LYMPHADENOPATHY; HEPATOMEGALY; HISTIOCYTE; HUMAN; HUMAN TISSUE; HYPERFERRITINEMIA; INTENSIVE CARE UNIT; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LABORATORY TEST; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MALAISE; MONONUCLEOSIS; MYALGIA; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PHARYNGITIS; RASH; REVIEW; SCREENING; SEPSIS; SEROLOGY; SKIN BIOPSY; SKIN PRURITUS; SLEEP DEPRIVATION; SORE THROAT; SPLENOMEGALY; URTICARIA; DERMATOMYOSITIS; ONSET AGE; PATHOLOGY; RECURRENT DISEASE; SKIN;

ADOLESCENT; AGE OF ONSET; DERMATOMYOSITIS; HUMANS; MACROPHAGE ACTIVATION SYNDROME; RECURRENCE; SKIN;

EID: 84908573047     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.05.009     Document Type: Review

References (25)

1. Rider L.G., Lindsley C.B., Cassidy J.T. Juvenile dermatomyositis. Textbook of Pediatric Rheumatology 2011, 375-413. Saunders. 6th edition.
2. Quartier P., Gherardi R.K. Juvenile dermatomyositis. Handbook of Clinical Neurology 2013, 1457-1463. Elsevier. 3rd ed.
3. Compeyrot-Lacassagne S., Feldman B.M. Inflammatory myopathies in children. Pediatr Clin N Am 2005, 52:493-520.
4. Batthish M., Feldman B.M. Juvenile dermatomyositis. Curr Rheumatol Rep 2011, 13:216-224.
5. Gowdie P.J., Allen R.C., Kornberg A.J., Akikusa J.D. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 2013, 16:561-567.
6. Walling H.W., Gerami P., Sontheimer R.D. Juvenile-onset clinically amyopathic dermatomyositis. Pediatr Drugs 2010, 12(1):23-34.
7. Janka G.E. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007, 166(2):95-109.
8. Szyper-Kravitz M. The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. IMAJ 2009, 11:633-634.
9. Janka G.E. Hemophagocytic syndromes. Blood Rev 2007, 21:245-253.
10. Gupta S., Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol 2010, 6:137-154.
11. Henter J.I., Horne A. Arico' M, Egeler RM, Filipovich AH, Imashuku S, Ladish S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007, 48:124-131.
12. Atteritano M., David A., Bagnato G., Beninati C., Frisina A., Iaria A., et al. Haemophagocytic syndrome in rheumatic patients: a systematic review. Eur Rev Med Pharmacol Sci 2012, 16:1414-1424.
13. Bazan-Socha S., Zolcinski M., Szostek M., Jurczyszyn A., Rucinnska M., Demczuk S., et al. A fatal case of acquired hemophagocytic lymphohistiocytosis (macrophage activation syndrome) in the initial course of dermatomyositis with anti-Jo1 antibody. Int J Rheum Dis 2013, X:1-4.
14. Sterba G., Rodriguez C., Sifontes S., Vigilanza P. Macrophage activation syndrome due to methotrexate in 12years old boy with dermatomyositis. J Rheumatol 2004, 31:1014-1015.
15. Lilleby V., Haydon J., Sanner H., Krossness B.K., Ringstad G., Flato B. Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. Scand J Rheumatol 2013, 43(2):171-173.
16. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-1138.
17. Vilaiyuk S., Sirachainan N., Wanitkun S., Pirojsakul K., Vaewpanich J. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol 2013, 32:899-904.
18. Parodi A., Davi S. pringe AB, Pistorio A, Ruperto N, Magni-Manzoni S et al. [Lupus working group of the Paediatric Rheumatology European Society]. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multi center study of thirty-eight patients. Arthritis Rheum 2009, 60:3388-3399.
19. Lin C.I., Yu H.H., Lee J.H., Wang L.C., Lin Y.T., Yang Y.H., et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 2012, 31:1223-1330.
20. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604.
21. Kelly A., Ramanan A.V. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007, 19:477-481.
22. Lehmberg K., Pink I., Eulenburg C., Beutel K., Maul-Pavicic A., Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 2013, 162:1245-1251.
23. Draborg A.H., Duus K., Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013, 1-9.
24. Niller H.H., Wolf H., Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008, 41(4):298-328.
25. Maakaroun N.R., Moanna A., Jacob J.T., Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol 2010, 20:93-105.